Thomas J. Schuetz Purchases 20,000 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) Stock

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) CEO Thomas J. Schuetz purchased 20,000 shares of Compass Therapeutics stock in a transaction that occurred on Tuesday, January 24th. The stock was acquired at an average cost of $4.19 per share, with a total value of $83,800.00. Following the acquisition, the chief executive officer now directly owns 5,451,873 shares in the company, valued at approximately $22,843,347.87. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Compass Therapeutics Stock Performance

Shares of CMPX stock traded up $0.60 during trading hours on Tuesday, reaching $4.41. The company had a trading volume of 358,819 shares, compared to its average volume of 351,395. The stock has a fifty day moving average of $4.70 and a 200-day moving average of $3.57. The company has a market capitalization of $556.50 million, a price-to-earnings ratio of -10.36 and a beta of 1.35. Compass Therapeutics, Inc. has a 12-month low of $1.25 and a 12-month high of $5.65.

Compass Therapeutics (NASDAQ:CMPX – Get Rating) last issued its quarterly earnings data on Wednesday, November 9th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). On average, analysts forecast that Compass Therapeutics, Inc. will post -0.39 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on CMPX. LADENBURG THALM/SH SH boosted their price objective on Compass Therapeutics to $9.00 in a research note on Wednesday, November 16th. EF Hutton Acquisition Co. I began coverage on Compass Therapeutics in a research note on Friday, December 16th. They set a “buy” rating and a $10.30 price objective for the company. Raymond James boosted their price objective on Compass Therapeutics from $5.00 to $8.00 and gave the stock an “outperform” rating in a research note on Thursday, November 10th. Finally, HC Wainwright cut their price objective on Compass Therapeutics from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, November 3rd. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $9.33.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp acquired a new position in Compass Therapeutics during the third quarter worth $55,000. Jane Street Group LLC acquired a new position in Compass Therapeutics during the third quarter worth $33,000. Vanguard Group Inc. lifted its stake in Compass Therapeutics by 58.5% during the third quarter. Vanguard Group Inc. now owns 2,380,623 shares of the company’s stock worth $5,428,000 after purchasing an additional 878,650 shares in the last quarter. Marshall Wace LLP raised its stake in shares of Compass Therapeutics by 118.4% in the third quarter. Marshall Wace LLP now owns 51,816 shares of the company’s stock valued at $117,000 after acquiring an additional 28,089 shares in the last quarter. Finally, Eventide Asset Management LLC acquired a new stake in shares of Compass Therapeutics in the third quarter valued at $2,509,000. 54.27% of the stock is currently owned by hedge funds and other institutional investors.

About Compass Therapeutics

(Get Rating)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137.